ClinicalTrials.gg
Sign In
RecruitingNCT03378739INOVASHOCKUpdated Mar 16, 2026

Inova Cardiogenic Shock Registry (INOVA SHOCK)

An observational study in Cardiogenic Shock, sponsored by Inova Health Care Services. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Inova Health Care Services · Observational

From the registry’s dates

  • Started Jan 2018; still recruiting 8 years 10 months later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years to 85 Years
Sex
All
01

Study summary

To collect retrospective clinical outcomes related to acute decompensated heart failure cardiogenic shock, acute myocardial infarction cardiogenic shock and compare current versus historical survival rates.

To collect Inova Heart and Vascular Institute (IHVI) site specific outcomes before and after initiation of the Cardiogenic Shock team on January 1, 2017.

To collect outcomes related to implementation of mechanical circulatory support versus no circulatory intervention and type of intervention (extracorporeal membrane oxygenation (ECMO) versus intracorporeal axial-flow (Impella).

  • Assess survival at three time points.
Read the detailed description

Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute shall be included in this registry. This includes adults with and without decision making capacity over the age of 18 years old.

The primary investigator (PI) will designate the data points to be included in the database in order to assess the efficiency of procedures and protocols in the treatment of cardiogenic shock at the IHVI as administered by the Shock team, to identify relationships between treatment and negative morbidity and mortality outcomes, and to monitor and improve quality of care delivered.

02

Conditions studied

  • Cardiogenic Shock

Keywords

  • cardiogenic
  • shock
03

In context

Shock, Cardiogenic

296 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 200 across 155 observational studies indexed under Shock, Cardiogenic.

Browse Shock, Cardiogenic studies →

Lead sponsor

Inova Health Care Services is the lead sponsor of 86 studies on the registry; 20 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients at the IHVI with documented Cardiogenic Shock team intervention for acute decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic shock

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Patients at the IHVI with documented Cardiogenic Shock team intervention for acute decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic shock.

Exclusion criteria

Exclusion Criteria:

-Patients under the age of 18 will be excluded.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Interventions

  • ProcedureCardiogenic Shock team activation

    Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.

06

What researchers measure

Primary outcomes

  1. Retrospective review of Cardiogenic shock patients outcomes

    To create an archive of retrospective clinical outcomes (acute decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic shock) and compare current versus historical survival rates.

    Time frame: 1 Year

07

Study locations

1 of 1 sites recruiting
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
    Recruiting
    • Behnam Tehrani, MD · Contact
    • Alex Truesdell, MD · Principal investigator
    • Benham Tehrani, MD · Sub investigator
08

References and documents

Publications

  • Sinha SS, Rosner CM, Tehrani BN, Maini A, Truesdell AG, Lee SB, Bagchi P, Cameron J, Damluji AA, Desai M, Desai SS, Epps KC, deFilippi C, Flanagan MC, Genovese L, Moukhachen H, Park JJ, Psotka MA, Raja A, Shah P, Sherwood MW, Singh R, Tang D, Young KD, Welch T, O'Connor CM, Batchelor WB. Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes. Circ Heart Fail. 2022 Jun;15(6):e009279. doi: 10.1161/CIRCHEARTFAILURE.121.009279. Epub 2022 May 5. PubMed 35510546 ↗
  • Tehrani B, Truesdell A, Singh R, Murphy C, Saulino P. Implementation of a Cardiogenic Shock Team and Clinical Outcomes (INOVA-SHOCK Registry): Observational and Retrospective Study. JMIR Res Protoc. 2018 Jun 28;7(6):e160. doi: 10.2196/resprot.9761. PubMed 29954728 ↗

Individual participant data

Plan to share: Yes — To facilitate both national and international research efforts in cardiogenic shock patient's collaborative studies may occur with other institutions outside of Inova.

Supporting information: Clinical study report

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Dec 2099, 983 months after the start.

Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 983 months is above that.

Counting every sponsor, half of 84 studies reached it within 45 months; a quarter within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2017
First posted
Dec 20, 2017
StartActual
Jan 1, 2018
Primary completionEst.
Dec 31, 2099
CompletionEst.
Dec 31, 2099
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03378739
Lead sponsor
Inova Health Care Services
Responsible party
Sponsor
First posted
Dec 20, 2017
Start date
Jan 1, 2018
Primary completion
Dec 31, 2099 (estimated)
Completion
Dec 31, 2099 (estimated)
Last update
Mar 16, 2026

Study contacts

Bhruga Shah
Contact
bhruga.shah@inova.org
703-776-2828
Vanessa Blumer, MD
principal investigator · Inova Health Care Services

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Shock, Cardiogenic →

Other studies from this sponsor

Inova Health Care Services

Start the discussion